By Siddhi Mahatole May 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment ...
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...
Though the Tecentriq SC has created buzz, oncologists say it is not about speed. It reflects how cancer care is evolving from ...
Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...
Morning Overview on MSN
A new gene-editing treatment just drove back advanced stomach and colon cancers in an early trial — by reprogramming patients’ own immune cells to hunt the tumors
Twelve people whose stomach or colon cancers had defeated every available treatment were infused with their own immune cells, ...
Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, ...
Krystal Biotech is the furthest along in pursuing this approach and is ironing out details of a registrational trial for its ...
Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...
People who got the injection, retatrutide, lost 28 percent of their body weight on average after 80 weeks, Eli Lilly said.
Skytrofa is now prescribed for growth hormone deficiency (GHD) in both adults and children ages 1 year and older who weigh at least 11.5 kilograms. Common side effects differ by age. Children often ...
The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results